AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30885839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (Group A)
Number of subjects: 315
Study 30885839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional dexamethasone (Group B)
Number of subjects: 315
Study 30885839 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (Group C)
Number of subjects: 315
Study 28789469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, play-based leg activity with weights for the affected leg and foot, 1 hour/day, 4 days/week for 12 weeks
Number of subjects: 0
Study 28789469 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly detailed)
Number of subjects: 0
Study 26964161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle treatment
Number of subjects: 60
Study 26964161 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment
Number of subjects: 60
Study 23394792 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 40
Study 23394792 — intervention group
Group type: COMPARATOR
Intervention: Laser acupuncture
Number of subjects: 40
Study 21828109 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing the pleura (Group A)
Number of subjects: 84
Study 21828109 — intervention group
Group type: COMPARATOR
Intervention: Instillation of minocycline (Group B)
Number of subjects: 84
Study 19519910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 17
Study 19519910 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition combined with Parenteral Nutrition (EN + PN)
Number of subjects: 17
Study 17966180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) device (Lumenis One)
Number of subjects: 8
Study 17966180 — intervention group
Group type: COMPARATOR
Intervention: Advanced fluorescent technology pulsed light (AFT, Harmony System)
Number of subjects: 8
Study 15124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with chemotherapy
Number of subjects: 0
Study 11269475 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized heparin dose calculated by an in vitro heparin dose‐response test (group HC)
Number of subjects: 26
Study 11269475 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of heparin (300 IU/kg; group C)
Number of subjects: 26
Study 9886723 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (100 mg twice daily)
Number of subjects: 110
Study 9886723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 8290176 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone (N = 25)
Number of subjects: 101
Study 8290176 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg) (N = 28)
Number of subjects: 101
Study 8290176 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise supplemented with conjugated equine estrogen (N = 28)
Number of subjects: 101
Study 8290176 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary) (N = 20)
Number of subjects: 101
Study 3569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg/d (Om10)
Number of subjects: 12
Study 3569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/d (Om20)
Number of subjects: 12
Study 3569737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 30032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised midazolam 0.2 mg kg‐1 (Group M)
Number of subjects: 90
Study 30032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised dexmedetomidine 2 μg kg‐1 (Group D)
Number of subjects: 90
Study 30032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ketamine 2 mg kg‐1 (Group K)
Number of subjects: 90
Study 26908681 — intervention group
Group type: EXPERIMENTAL
Intervention: MOC program participation
Number of subjects: 27
Study 23895199 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional labeling
Number of subjects: 410
Study 23895199 — intervention group
Group type: EXPERIMENTAL
Intervention: Social labeling
Number of subjects: 410
Study 23895199 — intervention group
Group type: COMPARATOR
Intervention: No label of previous donation (control condition)
Number of subjects: 410
Study 22508621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises
Number of subjects: 26
Study 22508621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic exercises)
Number of subjects: 26
Study 20360183 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAID
Number of subjects: 19
Study 20360183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NSAID
Number of subjects: 19
Study 20360183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (L15)
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (O10)
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (O20)
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (P40)
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: All PPIs
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (O20) and Pantoprazole (P40)
Number of subjects: 20
Study 18241283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (L15) and Omeprazole (O10)
Number of subjects: 20
Study 18482486 — intervention group
Group type: EXPERIMENTAL
Intervention: GP intervention group (IG)
Number of subjects: 209
Study 18482486 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group 1 (CG1)
Number of subjects: 209
Study 18482486 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group 2 (CG2)
Number of subjects: 209
Study 16167679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal washing using a 30ml ear‐syringe bulb (NWb)
Number of subjects: 200
Study 16167679 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal aspiration (NPA)
Number of subjects: 200
Study 16167679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal washing using a 5ml syringe (NWs)
Number of subjects: 200
Study 11744900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard anterior colporrhaphy
Number of subjects: 114
Study 11744900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus polyglactin 910 mesh
Number of subjects: 114
Study 11744900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralateral anterior colporrhaphy
Number of subjects: 114
Study 11744900 — intervention group
Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 114
Study 8978585 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg i.v. plus dexamethasone 20 mg i.v.
Number of subjects: 189
Study 8978585 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 60 mg i.v. plus dexamethasone 20 mg i.v.
Number of subjects: 189
Study 8496210 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression and rotator-cuff debridement
Number of subjects: 45
Study 8496210 — intervention group
Group type: COMPARATOR
Intervention: Open repair and acromioplasty
Number of subjects: 45
Study 2906344 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic gestodene/ethinyl estradiol
Number of subjects: 120
Study 2906344 — intervention group
Group type: COMPARATOR
Intervention: Triphasic levonorgestrel/ethinyl estradiol
Number of subjects: 120
Study 2906344 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic gestodene/ethinyl estradiol
Number of subjects: 120
Study 2906344 — intervention group
Group type: COMPARATOR
Intervention: Monophasic desogestrel/ethinyl estradiol
Number of subjects: 120
Study 30840530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest (VEST)
Number of subjects: 12
Study 30840530 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 12
Study 28605286 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine U300
Number of subjects: 22
Study 28605286 — intervention group
Group type: COMPARATOR
Intervention: Glargine U100
Number of subjects: 22
Study 26021996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0
Study 25632615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg, two hours prior to MVA)
Number of subjects: 80
Study 25632615 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (400 microg, two hours prior to MVA)
Number of subjects: 80
Study 25632615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sublingual and Oral)
Number of subjects: 80
Study 21277628 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ZEA/kg bw for 48 days
Number of subjects: 12
Study 21277628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg ZEA/kg bw for 48 days
Number of subjects: 12
Study 21277628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 days
Number of subjects: 12
Study 19217817 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (twice weekly for 15 weeks followed by 24 weeks of unsupervised training)
Number of subjects: 58
Study 19217817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 17196811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 141
Study 17196811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 17196811 — intervention group
Group type: EXPERIMENTAL
Intervention: All athletes (combined LGG and placebo)
Number of subjects: 141
Study 14693613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 200 mg/40 mL infiltrated at the wound site and continuous infusion of ropivacaine 0.2% at 5 mL/h for 55 hours
Number of subjects: 38
Study 14693613 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion at the same rate as the R group
Number of subjects: 38
Study 14693613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine continuous wound instillation
Number of subjects: 38
Study 11339491 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% age‐predicted maximal heart rate reserve (HRR)
Number of subjects: 24
Study 11339491 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% age‐predicted maximal heart rate reserve (HRR)
Number of subjects: 24
Study 11339491 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 24
Study 9152189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 200
Study 9152189 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 200
Study 8239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm antegrade blood cardioplegia
Number of subjects: 107
Study 8239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde blood cardioplegia
Number of subjects: 107
Study 8239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold antegrade blood cardioplegia
Number of subjects: 107
Study 8239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold retrograde blood cardioplegia
Number of subjects: 107
Study 8239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cold antegrade blood cardioplegia
Number of subjects: 107
Study 8239794 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia (general)
Number of subjects: 107
Study 3322480 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal myectomy
Number of subjects: 23
Study 3322480 — intervention group
Group type: COMPARATOR
Intervention: Anal dilatation
Number of subjects: 23
Study 30211001 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity aerobic exercise for 16 weeks
Number of subjects: 51
Study 30211001 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 27998386 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention to reduce heat-related illness
Number of subjects: 4556
Study 27998386 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 4556
Study 24917049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella Pro brace with supervised physiotherapy
Number of subjects: 156
Study 24917049 — intervention group
Group type: COMPARATOR
Intervention: Supervised physiotherapy alone
Number of subjects: 156
Study 22429066 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day continued
Number of subjects: 715
Study 22429066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after switching from milnacipran)
Number of subjects: 715
Study 22429066 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day discontinued
Number of subjects: 715
Study 19804497 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (group A)
Number of subjects: 74
Study 19804497 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (group B)
Number of subjects: 74
Study 18477073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative oral carbohydrate drink (400 ml, 2 hours before surgery)
Number of subjects: 101
Study 18477073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative oral carbohydrate drink
Number of subjects: 101
Study 18477073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drink given)
Number of subjects: 101
Study 16159645 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccination at 16 or 36 weeks after initiation of HAART
Number of subjects: 37
Study 16159645 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccination
Number of subjects: 37
Study 11966737 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 32
Study 11966737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10194013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate 4-strand repairs
Number of subjects: 40
Study 10194013 — intervention group
Group type: COMPARATOR
Intervention: Kessler, Strickland, and Savage repairs
Number of subjects: 40
Study 7670695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study 2180659 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group using an algorithm for adjustment of insulin dosage based on daily prebreakfast capillary blood glucose measurements
Number of subjects: 53
Study 2180659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 575318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20
Study 575318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 575318 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT group
Number of subjects: 20
Study 31288266 — intervention group
Group type: EXPERIMENTAL
Intervention: Zip device
Number of subjects: 25
Study 31288266 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 25
Study 31046870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic assisted powered adenoidectomy
Number of subjects: 50
Study 31046870 — intervention group
Group type: COMPARATOR
Intervention: Conventional curettage adenoidectomy
Number of subjects: 50
Study 28762645 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-Ret Overnight Cream (double-conjugate retinoid cream)
Number of subjects: 48
Study 25884390 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 75 mg once a day
Number of subjects: 109
Study 25884390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 109
Study 23712970 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets with 20% fat, 15% protein, 65% carbohydrates
Number of subjects: 710
Study 23712970 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets with 20% fat, 25% protein, 55% carbohydrates
Number of subjects: 710
Study 23712970 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets with 40% fat, 15% protein, 45% carbohydrates
Number of subjects: 710
Study 23712970 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diets with 40% fat, 25% protein, 35% carbohydrates
Number of subjects: 710
Study 21988544 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 80
Study 21988544 — intervention group
Group type: COMPARATOR
Intervention: Problem-Solving Therapy
Number of subjects: 80
Study 19640508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 56
Study 19640508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy, initially 2 microg/kg body weight/d, increased to a maximum of 12 microg/kg/d over 2 years.
Number of subjects: 67
Study 17280527 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 67
Study 17280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy in men.
Number of subjects: 67
Study 17280527 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in men.
Number of subjects: 67
Study 17280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy in women.
Number of subjects: 67
Study 17280527 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in women.
Number of subjects: 67
Study 17280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy.
Number of subjects: 67
Study 15491239 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 447
Study 15491239 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 447
Study 15491239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 11575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2‐2.5 microg kg(‐1) h(‐1)
Number of subjects: 20
Study 11575340 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1‐3 mg kg(‐1) h(‐1)
Number of subjects: 20
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGF-BB pre-treated dentine surface (group 2)
Number of subjects: 80
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDGF-BB and IGF-1 pre-treated dentine surface (group 4)
Number of subjects: 80
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGF-BB treated TTC conditioned dentine surface (group 6)
Number of subjects: 80
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 pre-treated dentine surface (group 3)
Number of subjects: 80
Study 9650878 — intervention group
Group type: COMPARATOR
Intervention: TTC conditioned dentine surfaces (group 5)
Number of subjects: 80
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC conditioned dentine surfaces treated with IGF-1 (group 7)
Number of subjects: 80
Study 9650878 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC conditioned dentine surfaces treated with combination of PDGF-BB and IGF-1 (group 8)
Number of subjects: 80
Study 8595787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 1000
Study 8595787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 2649987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 203
Study 2649987 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB (cisplatin, vinblastine, bleomycin) plus ifosfamide
Number of subjects: 203
Study 2649987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide-containing regimens
Number of subjects: 203
Study 2649987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, etoposide, and ifosfamide combination
Number of subjects: 203
Study 2649987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide in first-line treatment
Number of subjects: 203
Study 339283 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(S)15-methyl prostaglandin F2alpha administered as a single intramuscular injection (0.6 mg)
Number of subjects: 30
Study 339283 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(S)15-methyl prostaglandin F2alpha administered as vaginal suppositories (1.0 or 1.5 mg per suppository)
Number of subjects: 30
Study 339283 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection (Group I)
Number of subjects: 30
Study 339283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories (Group II)
Number of subjects: 30
Study 30776918 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing an anxiety-inducing film fragment
Number of subjects: 277
Study 30776918 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving a short presentation to an audience (impromptu speech task)
Number of subjects: 277
Study 30776918 — intervention group
Group type: COMPARATOR
Intervention: Watching another person's presentation (control condition)
Number of subjects: 277
Study 30024027 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA) treatment along with sleep hygiene practices
Number of subjects: 47
Study 30024027 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving sleep hygiene practices alone
Number of subjects: 47
Study 27067882 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (5-Hz, 10 daily sessions)
Number of subjects: 41
Study 27067882 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 41
Study 25391168 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Infloran: Lactobacillus acidophilus 1 x 10(9) and Bifidobacterium bifidum 1 x 10(9) organisms) at a dose of 125 mg/kg/dose twice a day for 6 weeks or until discharge
Number of subjects: 60
Study 25391168 — intervention group
Group type: COMPARATOR
Intervention: Control group (breast milk or premature formula alone)
Number of subjects: 60
Study 25391168 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Infloran)
Number of subjects: 60
Study 21925682 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitifadine 25 mg BID for 2 weeks, then 50 mg BID for 4 weeks
Number of subjects: 63
Study 21925682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21925682 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitifadine
Number of subjects: 63